搜尋結果
In June 2023, the FDA advised manufacturers that the 2023–2024 formulation of the COVID-19 vaccines for use in the US be updated to be a monovalent COVID-19 vaccine using the XBB.1.5 lineage of the Omicron variant.
- none
- Intramuscular
- mRNA, viral, inactivated, protein
- SARS-CoV-2
The COVID-19 pandemic, also known as the coronavirus pandemic, is a global pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The novel virus was first identified in an outbreak in Wuhan, the capital of Hubei, China, in December 2019, before it spread to other areas of Asia, and then worldwide in early 2020.
- 6,956,160 (reported), 17.5–31.4 million (estimated)
- Worldwide
- Coronavirus disease 2019 (COVID-19)
- Severe acute respiratory syndromecoronavirus 2 (SARS‑CoV‑2)
Coronavirus disease 2019 (COVID-19) is a contagious disease caused by the coronavirus SARS-CoV-2. The first known case was identified in Wuhan, China, in December 2019.[7] The disease quickly spread worldwide, resulting in the COVID-19 pandemic. The symptoms of COVID‑19 are variable but often include fever,[8] fatigue, cough, breathing ...
- 6,960,770 (reported), 17.6–31.4 million (estimated)
- SARS-CoV-2
- 2–14 days (typically 5), after infection
- Symptomatic and supportive
XBB, a recombinant of the BA.2.10.1.1 and BA.2.75.3.1.1.1 sublineages, is an Omicron subvariant first detected in August 2022. [178] On 20 October 2022, the chief scientist of the World Health Organization (WHO), Soumya Swaminathan, warned that the XBB subvariant of Omicron may cause infections in some countries while the severity of ...
- Technology
- Vaccine Development
- Investment
- See Also
The Vaxart technology is based on the potential to prevent or inhibit infectious diseases by using orally-delivered vaccines by tablets, eliminating intramuscular injection concerns which may involve pain, fear of needles, cross-contamination, dosing inconsistencies, and higher cost for large-scale immunizations. As a proof of concept for oral vacc...
Influenza Vaccine
The lead vaccine candidate by Vaxart is an influenza oral tablet vaccine, which showed safety and neutralizing antibody responses to influenza virus in a 2015 Phase I clinical trial. A 2016-17 Phase II trial of the Vaxart oral flu vaccine, VXA-A1.1, showed that the vaccine was well-tolerated and provided immunity against virus shedding, outperforming the effectiveness of an established intramuscular vaccine. In 2018, Vaxart completed a Phase II challenge study, in which the Vaxart influenza t...
COVID-19 vaccine
In January 2020, Vaxart announced development of a tablet vaccine to inhibit COVID-19. Some of its competitors were companies such as Novavax, Inovio Pharmaceuticals, and Moderna. In February 2020, Vaxart began a program to develop an oral tablet vaccine for COVID-19. In April, the company reported positive immune responses in laboratory animals from its tests with a vaccine candidate for COVID-19. In January 2024, Vaxart received a grant from the United States Biomedical Advanced Research an...
Norovirus vaccine
Vaxart has been progressing in the development of an oral tablet vaccine for Norovirus, the leading cause of acute gastroenteritis globally. Norovirus significantly impacts all age groups, particularly young children and the elderly, causing millions of cases annually with substantial healthcare and economic burdens. Its vaccine candidate is a bivalent oral tablet targeting major norovirus genogroups GI and GII. The tablet form is specifically crafted to generate antibodies in the intestine,...
In 2019, several hedge fundsinvested in Vaxart, with the largest investment coming from Armistice Capital which acquired 25.2 million shares.
CRISPR (/ ˈ k r ɪ s p ər /) (an acronym for clustered regularly interspaced short palindromic repeats) is a family of DNA sequences found in the genomes of prokaryotic organisms such as bacteria and archaea. These sequences are derived from DNA fragments of bacteriophages that had previously infected the prokaryote. ...
The Airbus A350 is a long-range, wide-body twin-engine airliner developed and produced by Airbus. The initial A350 design proposed by Airbus in 2004, in response to the Boeing 787 Dreamliner, would have been a development of the Airbus A330 with composite wings and new engines. Due to inadequate market support, Airbus switched in 2006 to a ...
